Latest Cell Therapeutics (CTIC) Headlines Geron
Post# of 74
Posted On: 03/13/2014 7:18:25 AM
Latest Cell Therapeutics (CTIC) Headlines
Geron: FDA Suspends Key Myelofibrosis Drug Due to Liver Safety Concerns
at The Street - Wed Mar 12, 8:57AM CDT
The FDA's clinical hold placed on Geron's imetelstat means all clinical trials are suspended.
Insider Trading Alert - CTIC, TCBI And FCS Traded By Insiders
at The Street - Mon Mar 10, 12:16PM CDT
Stocks with insider trader activity include CTIC, TCBI and FCS
Cell Therapeutics to Present at the 26th Annual ROTH Conference
PR Newswire - Wed Mar 05, 12:30AM CST
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today that management will present at the ROTH Capital Partners 26th Annual Conference on Tuesday, March 11 at 11:30 a.m. PST/2:30 p.m. EST/7:30 p.m. CET in Dana Point, CA.
Cell Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results
PR Newswire - Tue Mar 04, 3:00PM CST
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported financial results for the fourth quarter and full year ended December 31, 2013.
Today's Biggest Biotech Stories: Roche, Regeneron, Cell Therapeutics, and AstraZeneca
Leo Sun, The Motley Fool - Motley Fool - Mon Mar 03, 8:28AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at four stocks -- Roche , Regeneron , ...
CTI Opens Enrollment for PERSIST-2 Phase 3 Trial of Pacritinib for Patients with Myelofibrosis Who Have Low Platelet Counts
PR Newswire - Mon Mar 03, 12:30AM CST
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced the initiation of a Phase 3 clinical trial, known as PERSIST-2, which will evaluate pacritinib, a novel, investigational JAK2/FLT3 inhibitor, in patients with myelofibrosis whose platelet counts are less than or equal to 100,000 per microliter (uL). The trial is expected to enroll up to 300 patients in North America, Europe, Australia and New Zealand within 12 to 14 months. In October 2013, CTI reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the PERSIST-2 trial, which is a written agreement between CTI and the FDA regarding the planned design, endpoints and statistical analysis approach of the trial to be used in support of a potential New Drug Application, or NDA, submission. PERSIST-2 is the second of two planned Phase 3 trials in the pacritinib development program for myelofibrosis.
NICE Publishes Final Guidance on PIXUVRI® (pixantrone)
PR Newswire - Thu Feb 27, 12:30AM CST
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported that the National Institute for Health and Care Excellence (NICE), the independent body responsible for driving improvement and excellence in the health and social care system in the UK, has published final guidance recommending prescription of PIXUVRI® (pixantrone) as a cost-effective monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (aggressive B-cell NHL), which includes diffuse large B-cell lymphoma. CTI estimates that there are approximately 1,600 to 1,800 people in the UK diagnosed with multiply relapsed aggressive B-cell NHL per year.
NewLink's Pancreatic Cancer Vaccine and the Feuerstein-Ratain Rule
at The Street - Wed Feb 26, 6:33AM CST
If history repeats, investor optimism for NewLink's phase III study is misplaced.
Cell Therapeutics to Report Fourth Quarter and Full Year 2013 Financial Results on March 4, 2014
PR Newswire - Tue Feb 25, 12:30AM CST
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today that it will report its fourth quarter and full year 2013 financial results on Tuesday, March 4, 2014, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a webcast conference call to discuss the results and provide a general corporate update at 4:30 p.m. ET (1:30 p.m. PT). Access to the event can be obtained as follows:
Glu Mobile and Siri XM Stock Volume Soars on Fourth-Quarter Results: Glu Mobile Inc.'s (NASDAQ: GLUU), Sirius XM Holdings Inc. (NASDAQ: SIRI), Zynga Inc. (NASDAQ:ZNGA, Cell Therapeutics Inc. (NASDAQ:CTIC)
ACCESSWIRE - Tue Feb 11, 9:11AM CST
On Feb 10, 2014 smartphone game maker Glu Mobile Inc.'s (NASDAQ: GLUU) stock volume soared with 4,266,674 shares changing hands, substantially higher than its three-month average volume of 3,400,832 shares.
Hot Stock: Cell Therapeutics, Shares Gain 16.4% (CTIC)
Comtex SmarTrend(R) - Fri Feb 07, 12:47PM CST
Cell Therapeutics (NASDAQ:CTIC) is one of today's best performing low-priced stocks, up 16.4% to $3.29 on 1.1x average daily volume. Thus far today, Cell Therapeutics has traded 7.8 million shares, vs. average volume of 7.2 million shares per day. The stock has outperformed the Dow (16.4% to the Dow's 0.8%) and outperformed the S&P 500 (16.4% to the S&P's 1.0%) during today's trading.
Cell Therapeutics appoints Karen Ignagni as director
M2 - Mon Feb 03, 4:43AM CST
US-based biopharmaceutical company Cell Therapeutics Inc (NASDAQ:CTIC)(MTA:CTIC) revealed on Monday Karen Ignagni has been appointed as its director with immediate effect.
Cell Therapeutics Appoints Karen Ignagni to Board of Directors
PR Newswire - Mon Feb 03, 12:30AM CST
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that Karen Ignagni has been appointed a Director of CTI, effective immediately. Ms. Ignagni currently serves as President and Chief Executive Officer of America's Health Insurance Plans (AHIP), which is the trade association representing U.S. health plans, serving members that provide healthcare, long-term care, dental and disability benefits to more than 200 million Americans.
Biotech Stock Mailbag: Cell Therapeutics and the Ariad Hostile React-o-Meter Meltdown
at The Street - Fri Jan 31, 5:00AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Cell Therapeutics Inc begins Phase 2 clinical trial of pacritinib in adult patients with relapsed acute myeloid leukemia under Cardiff University and Cancer Research UK
M2 - Thu Jan 30, 3:24AM CST
Biopharmaceutical company Cell Therapeutics Inc (NASDAQ:CTIC)(MTA:CTIC) reported on Thursday the launch of an international cooperative group Phase 2 clinical trial of pacritinib in adult patients with relapsed acute myeloid leukemia (AML) with mutations of the FLT3 gene that is found in one-third of AML patients and is an independent risk factor for poor prognosis.
CTI Announces United Kingdom National Cancer Research Institute AML Cooperative Group Phase 2 Trial Evaluating Pacritinib for Patients with Relapsed FLT3 Positive Acute Myeloid Leukemia
PR Newswire - Thu Jan 30, 12:30AM CST
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced the initiation of an international cooperative group Phase 2 clinical trial of pacritinib in adult patients with relapsed acute myeloid leukemia (AML) with mutations of the FLT3 gene. Mutation of the FLT3 gene is found in approximately one-third of AML patients and is an independent risk factor for poor prognosis. Pacritinib is an oral JAK2/FLT3 inhibitor that has demonstrated encouraging activity in preclinical models of AML with mutated FLT3 gene, including additional FLT3 mutations that confer resistance to other targeted FLT3 agents. The trial is being conducted by the AML Working Group of the National Cancer Research Institute Haematological Oncology Study Group in Acute Myeloid Leukemia (AML) and high risk Myelodysplastic Syndrome (MDS) under the sponsorship of Cardiff University and supported by Cancer Research UK. The trial management group is lead by Professor Alan K. Burnett, Head of Haematology in the Department of Medical Genetics, Haematology and Pathology at the School of Medicine at Cardiff University.
Cell Therapeutics Announces GOG Completes Patient Enrollment in GOG-0212 Phase 3 Clinical Trial of Paclitaxel Poliglumex (Opaxio(TM)) as Maintenance Therapy in Ovarian Cancer
PR Newswire - Tue Jan 28, 12:30AM CST
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that the Gynecologic Oncology Group (GOG) informed CTI that it has completed patient enrollment in the GOG-0212 Phase 3 clinical trial of investigational agent paclitaxel poliglumex (Opaxio(TM) ) as maintenance therapy in ovarian cancer.
Can You Still Ride This Month's 3 Biggest Winners To Greater Gains?
Alex Planes, The Motley Fool - Motley Fool - Mon Jan 27, 11:15AM CST
One of the best things about being a long-term investor is that the law of gravity need not apply to good stocks -- what goes up doesn't necessarily have to come down. But some stocks can still fly too close to the sun, singing investors who bought...
3 Stocks to Get on Your Watchlist
Sean Williams, The Motley Fool - Motley Fool - Wed Jan 22, 4:05PM CST
I follow quite a lot of companies, so the usefulness of a watchlist to me cannot be overstated. Without my watchlist, I'd be unable to keep up with my favorite sectors and see what's really moving the market. Even worse, I'd be lost when the time...
Most active Nasdaq-traded stocks
AP - Wed Jan 22, 12:47PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.:
Geron: FDA Suspends Key Myelofibrosis Drug Due to Liver Safety Concerns
at The Street - Wed Mar 12, 8:57AM CDT
The FDA's clinical hold placed on Geron's imetelstat means all clinical trials are suspended.
Insider Trading Alert - CTIC, TCBI And FCS Traded By Insiders
at The Street - Mon Mar 10, 12:16PM CDT
Stocks with insider trader activity include CTIC, TCBI and FCS
Cell Therapeutics to Present at the 26th Annual ROTH Conference
PR Newswire - Wed Mar 05, 12:30AM CST
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today that management will present at the ROTH Capital Partners 26th Annual Conference on Tuesday, March 11 at 11:30 a.m. PST/2:30 p.m. EST/7:30 p.m. CET in Dana Point, CA.
Cell Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results
PR Newswire - Tue Mar 04, 3:00PM CST
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported financial results for the fourth quarter and full year ended December 31, 2013.
Today's Biggest Biotech Stories: Roche, Regeneron, Cell Therapeutics, and AstraZeneca
Leo Sun, The Motley Fool - Motley Fool - Mon Mar 03, 8:28AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at four stocks -- Roche , Regeneron , ...
CTI Opens Enrollment for PERSIST-2 Phase 3 Trial of Pacritinib for Patients with Myelofibrosis Who Have Low Platelet Counts
PR Newswire - Mon Mar 03, 12:30AM CST
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced the initiation of a Phase 3 clinical trial, known as PERSIST-2, which will evaluate pacritinib, a novel, investigational JAK2/FLT3 inhibitor, in patients with myelofibrosis whose platelet counts are less than or equal to 100,000 per microliter (uL). The trial is expected to enroll up to 300 patients in North America, Europe, Australia and New Zealand within 12 to 14 months. In October 2013, CTI reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the PERSIST-2 trial, which is a written agreement between CTI and the FDA regarding the planned design, endpoints and statistical analysis approach of the trial to be used in support of a potential New Drug Application, or NDA, submission. PERSIST-2 is the second of two planned Phase 3 trials in the pacritinib development program for myelofibrosis.
NICE Publishes Final Guidance on PIXUVRI® (pixantrone)
PR Newswire - Thu Feb 27, 12:30AM CST
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported that the National Institute for Health and Care Excellence (NICE), the independent body responsible for driving improvement and excellence in the health and social care system in the UK, has published final guidance recommending prescription of PIXUVRI® (pixantrone) as a cost-effective monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (aggressive B-cell NHL), which includes diffuse large B-cell lymphoma. CTI estimates that there are approximately 1,600 to 1,800 people in the UK diagnosed with multiply relapsed aggressive B-cell NHL per year.
NewLink's Pancreatic Cancer Vaccine and the Feuerstein-Ratain Rule
at The Street - Wed Feb 26, 6:33AM CST
If history repeats, investor optimism for NewLink's phase III study is misplaced.
Cell Therapeutics to Report Fourth Quarter and Full Year 2013 Financial Results on March 4, 2014
PR Newswire - Tue Feb 25, 12:30AM CST
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today that it will report its fourth quarter and full year 2013 financial results on Tuesday, March 4, 2014, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a webcast conference call to discuss the results and provide a general corporate update at 4:30 p.m. ET (1:30 p.m. PT). Access to the event can be obtained as follows:
Glu Mobile and Siri XM Stock Volume Soars on Fourth-Quarter Results: Glu Mobile Inc.'s (NASDAQ: GLUU), Sirius XM Holdings Inc. (NASDAQ: SIRI), Zynga Inc. (NASDAQ:ZNGA, Cell Therapeutics Inc. (NASDAQ:CTIC)
ACCESSWIRE - Tue Feb 11, 9:11AM CST
On Feb 10, 2014 smartphone game maker Glu Mobile Inc.'s (NASDAQ: GLUU) stock volume soared with 4,266,674 shares changing hands, substantially higher than its three-month average volume of 3,400,832 shares.
Hot Stock: Cell Therapeutics, Shares Gain 16.4% (CTIC)
Comtex SmarTrend(R) - Fri Feb 07, 12:47PM CST
Cell Therapeutics (NASDAQ:CTIC) is one of today's best performing low-priced stocks, up 16.4% to $3.29 on 1.1x average daily volume. Thus far today, Cell Therapeutics has traded 7.8 million shares, vs. average volume of 7.2 million shares per day. The stock has outperformed the Dow (16.4% to the Dow's 0.8%) and outperformed the S&P 500 (16.4% to the S&P's 1.0%) during today's trading.
Cell Therapeutics appoints Karen Ignagni as director
M2 - Mon Feb 03, 4:43AM CST
US-based biopharmaceutical company Cell Therapeutics Inc (NASDAQ:CTIC)(MTA:CTIC) revealed on Monday Karen Ignagni has been appointed as its director with immediate effect.
Cell Therapeutics Appoints Karen Ignagni to Board of Directors
PR Newswire - Mon Feb 03, 12:30AM CST
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that Karen Ignagni has been appointed a Director of CTI, effective immediately. Ms. Ignagni currently serves as President and Chief Executive Officer of America's Health Insurance Plans (AHIP), which is the trade association representing U.S. health plans, serving members that provide healthcare, long-term care, dental and disability benefits to more than 200 million Americans.
Biotech Stock Mailbag: Cell Therapeutics and the Ariad Hostile React-o-Meter Meltdown
at The Street - Fri Jan 31, 5:00AM CST
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Cell Therapeutics Inc begins Phase 2 clinical trial of pacritinib in adult patients with relapsed acute myeloid leukemia under Cardiff University and Cancer Research UK
M2 - Thu Jan 30, 3:24AM CST
Biopharmaceutical company Cell Therapeutics Inc (NASDAQ:CTIC)(MTA:CTIC) reported on Thursday the launch of an international cooperative group Phase 2 clinical trial of pacritinib in adult patients with relapsed acute myeloid leukemia (AML) with mutations of the FLT3 gene that is found in one-third of AML patients and is an independent risk factor for poor prognosis.
CTI Announces United Kingdom National Cancer Research Institute AML Cooperative Group Phase 2 Trial Evaluating Pacritinib for Patients with Relapsed FLT3 Positive Acute Myeloid Leukemia
PR Newswire - Thu Jan 30, 12:30AM CST
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced the initiation of an international cooperative group Phase 2 clinical trial of pacritinib in adult patients with relapsed acute myeloid leukemia (AML) with mutations of the FLT3 gene. Mutation of the FLT3 gene is found in approximately one-third of AML patients and is an independent risk factor for poor prognosis. Pacritinib is an oral JAK2/FLT3 inhibitor that has demonstrated encouraging activity in preclinical models of AML with mutated FLT3 gene, including additional FLT3 mutations that confer resistance to other targeted FLT3 agents. The trial is being conducted by the AML Working Group of the National Cancer Research Institute Haematological Oncology Study Group in Acute Myeloid Leukemia (AML) and high risk Myelodysplastic Syndrome (MDS) under the sponsorship of Cardiff University and supported by Cancer Research UK. The trial management group is lead by Professor Alan K. Burnett, Head of Haematology in the Department of Medical Genetics, Haematology and Pathology at the School of Medicine at Cardiff University.
Cell Therapeutics Announces GOG Completes Patient Enrollment in GOG-0212 Phase 3 Clinical Trial of Paclitaxel Poliglumex (Opaxio(TM)) as Maintenance Therapy in Ovarian Cancer
PR Newswire - Tue Jan 28, 12:30AM CST
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that the Gynecologic Oncology Group (GOG) informed CTI that it has completed patient enrollment in the GOG-0212 Phase 3 clinical trial of investigational agent paclitaxel poliglumex (Opaxio(TM) ) as maintenance therapy in ovarian cancer.
Can You Still Ride This Month's 3 Biggest Winners To Greater Gains?
Alex Planes, The Motley Fool - Motley Fool - Mon Jan 27, 11:15AM CST
One of the best things about being a long-term investor is that the law of gravity need not apply to good stocks -- what goes up doesn't necessarily have to come down. But some stocks can still fly too close to the sun, singing investors who bought...
3 Stocks to Get on Your Watchlist
Sean Williams, The Motley Fool - Motley Fool - Wed Jan 22, 4:05PM CST
I follow quite a lot of companies, so the usefulness of a watchlist to me cannot be overstated. Without my watchlist, I'd be unable to keep up with my favorite sectors and see what's really moving the market. Even worse, I'd be lost when the time...
Most active Nasdaq-traded stocks
AP - Wed Jan 22, 12:47PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.:
(0)
(0)CTI BioPharma Corp. (CTIC) Stock Research Links
Scroll down for more posts ▼